A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy.

A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy.

Chemotherapy-induced neuropathy is the principle dose limiting factor requiring discontinuation of many chemotherapeutic agents, including cisplatin and oxaliplatin. About 30 to 40% of patients receiving chemotherapy develop pain and sensory changes. Given that poly (ADP-ribose) polymerase (PARP) in...

Full description

Bibliographic Details
Main Authors: Lauren E Ta, James D Schmelzer, Allan J Bieber, Charles L Loprinzi, Gary C Sieck, Jill D Brederson, Philip A Low, Anthony J Windebank
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3542321?pdf=render

Internet

http://europepmc.org/articles/PMC3542321?pdf=render

Similar Items